Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.

Autor:	Mahapatro A; Hi-Tech Medical College and Hospital, Rourkela, Odisha, India., Bozorgi A; Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Obulareddy SUJ; University of Arkansas, Little Rock, Arkansas, USA., Jain SM; MVJ Medical College and Research Hospital, Bengaluru, India., Reddy Korsapati R; University of Toledo, Toledo, Ohio, USA., Kumar A; Baylor College of Medicine, Houston, USA., Patel K; Shenyang North New Area, Shenyang, Liaoning Province, People's Republic of China., Soltani Moghadam S; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran., Arya A; Department of Internal Medicine III, Halle University Hospital, Halle (Saale), Germany., Jameel Alotaibi A; Vision Colleges, Riyadh, Saudi Arabia., Keivanlou MH; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran., Hassanipour S; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran., Hasanpour M; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran., Amini-Salehi E; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Jazyk:	angličtina
Zdroj:	Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2024 Sep 25; Vol. 86 (11), pp. 6602-6618. Date of Electronic Publication: 2024 Sep 25 (Print Publication: 2024).
DOI:	10.1097/MS9.0000000000002592
Abstrakt:	Background: In recent years, glucagon-like peptide-1 (GLP-1) agonists have garnered increasing attention for their potential cardiovascular benefits beyond glycemic control in patients with diabetes. Understanding the research landscape surrounding GLP-1 agonists and cardiovascular diseases (CVDs) is crucial for informing clinical practice and guiding future research endeavors. This bibliometric analysis aimed to comprehensively assess the scholarly output and trends in this field, shedding light on the evolving landscape of GLP-1 agonists' role in cardiovascular health. Methods: The publications concerning GLP-1 agonists in CVDs were gathered from the Web of Science Core Collection, and visualizations were created utilizing Excel 2019, Cite Space, and VOS viewer software. Results and Conclusion: Using bibliometric and visual methods, the research hotspots and trends regarding GLP-1 agonists in cardiovascular diseases were pinpointed. Additionally, a thriving interest in GLP-1 agonists research within cardiovascular medicine was observed, with a notable surge in publications from 2016 onwards. The analysis revealed that the United States and China are the leading contributors, accounting for over 50% of the total publications. The University of Copenhagen and the University of Toronto emerged as the most prolific institutions in this field. Co-citation analysis highlighted the influential role of landmark clinical trials, such as the LEADER, ELIXA, and EXSCEL. Keyword trend analysis identified the emergence of newer GLP-1 agonists, such as tirzepatide and semaglutide, as well as a growing focus on topics like 'healthy obesity' and chronic kidney disease. These findings suggest that the research landscape is evolving, with a focus on expanding the therapeutic applications of GLP-1 agonists beyond glycemic control. Overall, this bibliometric analysis provided insights into the current state and future directions of research on GLP-1 agonists and their impact on cardiovascular health, guiding future research endeavors, and informing clinical practice. Competing Interests: The authors declare no competing interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu